Intel

Accelerating Precision Medicine

Accelerating Precision Medicine

Cancer treatment isn’t one-size-fits-all

Surgery, radiation, chemotherapy—in the past, cancer patients really only had three options when it came to care. But today, with the implementation of genomic sequencing, healthcare providers are able to use a patient’s own genetic data to tailor a treatment plan for each patient’s specific needs.

The first of three reports, this paper explores a programmatic approach that healthcare delivery organizations can take to implement Precision Medicine practices into their clinical settings. In their research, Gartner found that “by 2020, some form of predictive or prescriptive algorithm will be embedded in 75% of all healthcare delivery processes.1” So, while challenging, operationalizing Precision Medicine is achievable with time to integrate, evaluate, and institutionalize.

This report looks at a framework for optimizing Precision Medicine investments, including:

  • Infusing Precision Medicine into governance body
  • Developing a scalable platform approach
  • Accelerating genomics and Precision Medicine adoption by engaging a partner ecosystem
  • Integrating data into current decision support systems and developing business models that leverage these genomics and Precision Medicine investments

Armed with this framework, healthcare providers will be better equipped to optimize their care while delivering targeted treatments that track towards the possibility of a cancer free future.